低剂量糖皮质激素治疗类风湿关节炎2年对骨密度和骨折的影响
该系统综述与个体参与者数据荟萃分析纳入5项随机试验的1112例类风湿关节炎患者,比较≤7.5 mg/天泼尼松等效剂量的糖皮质激素与安慰剂或标准治疗。结果显示,治疗2年后糖皮质激素组腰椎骨密度下降更明显,股骨骨密度无显著差异,骨折风险两组相当。
要点
- 低剂量糖皮质激素治疗2年导致类风湿关节炎患者腰椎骨密度下降,股骨骨密度未受影响。
- 两组骨折风险相当,但发生骨折的参与者数量较少。
- 亚组分析未发现腰椎骨丢失的易感人群。
核心结论
- 低剂量糖皮质激素用于治疗类风湿关节炎2年,导致腰椎骨密度下降,但股骨骨密度未下降。
- 骨折风险在糖皮质激素组与对照组之间相当。
研究设计与样本
- 系统文献综述与个体参与者数据荟萃分析,纳入比较≤7.5 mg/天泼尼松等效剂量糖皮质激素与安慰剂或标准治疗的随机试验。
- 共纳入5项试验的1112例早期和已确诊类风湿关节炎患者,所有患者均可接受改善病情抗风湿药背景治疗。
主要发现
- 与对照组相比,糖皮质激素组腰椎骨密度下降更明显(-0.021 g/cm²;95% CI -0.037至-0.005;p=0.034;I²=31%)。
- 股骨骨密度变化两组无显著差异(0.004 g/cm²;95% CI -0.008至0.016;p=0.47;I²=0%)。
- 35例参与者发生至少1次骨折,两组骨折风险相当。
- 亚组分析未发现腰椎骨丢失的易感人群,敏感性分析结果一致。
关键数值与推荐
- 糖皮质激素剂量为≤7.5 mg/天泼尼松等效剂量。
- 共同主要终点为2年内腰椎和股骨骨密度变化以及意向性治疗人群中发生至少1次临床骨折的参与者。
临床怎么用
- 使用低剂量糖皮质激素治疗类风湿关节炎时,应关注腰椎骨密度变化。
- 尽管骨折风险未显著增加,仍需对患者进行骨折风险评估。
局限性
- 仅5项试验提供个体参与者数据,骨折事件数量较少(35例)。
- 研究期限为2年,长期影响未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effects of 2 years of low-dose glucocorticoid (GC) treatment on bone mineral density and fracture risk in patients with rheumatoid arthritis (RA). METHODS: We performed a protocolised (dx.doi.org/10.17504/protocols.io.6qpvr3ombvmk/v1) systematic literature review and individual participant data meta-analysis of randomised trials in early and established RA, which compared GCs at ≤7.5 mg prednisone equivalent/day with placebo or standard of care. All patients could receive background treatment with disease-modifying antirheumatic drugs. Changes in lumbar spine and femoral bone density and participants with ≥1 clinical fracture over 2 years in intention-to-treat analyses were coprimary endpoints. Main analyses were based on one-stage models; I² was estimated from two-stage models. Missing data were handled using multiple imputation. Several sensitivity analyses assessed the robustness of our results. RESULTS: Out of 2336 articles, five out of six identified trials provided individual participant data (1112 participants). Greater bone loss was observed at the lumbar spine in the GC compared with the control group (-0.021 g/cm²; 95% CI -0.037 to -0.005; p=0.034; I²=31%) but not at the femur (0.004 g/cm²; 95% CI -0.008 to 0.016; p=0.47; I²=0%). Subgroup analyses did not reveal groups particularly susceptible to GC-induced bone loss at the lumbar spine. 35 participants experienced ≥1 fracture; fracture risk was comparable in both groups. Sensitivity analyses yielded consistent results. CONCLUSION: Low-dose GCs, used for 2 years to treat RA, lead to bone loss at the lumbar spine but not at the femur.
引用
- Palmowski A, Haugegaard T, Hafström I, et al. Changes in bone mineral density and fractures during 2 years of low-dose glucocorticoid treatment for rheumatoid arthritis: a systematic literature review and individual participant data meta-analysis. RMD Open. 2026. PMID: 42097691. doi:10.1136/rmdopen-2025-006615
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。